South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 Clinical Trial
– SRP-001, a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics – – Data expected in 3Q 2023 – NEW ORLEANS, Aug. 22, 2023…
Comments Off on South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 Clinical Trial